Clin Cancer Res 1997, 3: 81–85.PubMed 19. Yousef GM, Diamandis Selleckchem Stattic EP: The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev 1992, 22: 184–204.CrossRef 20. Berner A, Nesland JM, Waehre H, Silde J, Fosså SD: Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens. Br J Cancer 1993, 68: 380–384.PubMedCrossRef 21. Lilja H, Christensson A, Dahlén U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T: Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991, 37: 1618–1625.PubMed 22. Williams SA, Singh P, Isaacs JT, Denmeade SR: Does PSA play a
role AZD1390 clinical trial as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007, 67: 312–329.PubMedCrossRef 23. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991, 145: 907–923.PubMed 24. Stege R, Grande M, Carlström K, Tribukait B, Pousette A: Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 2000, 6: 160–165.PubMed 25. Arakawa A, Soh
S, Chakraborty S, Scardino PT, Wheeler TM: Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen. Prostate Cancer and Prostatic Dis 1997, 1: 32–38.CrossRef 26. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH:
Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006, 26: 5310–5324.PubMedCrossRef 27. Nielson GK, Sojka K, Trumbull K, Spaulding B, Welcher R: Immunohistochemical characterization old of prostate specific membrane antigen expression in the vasculature of normal and neoplastic tissues. Modern Path 2004, 17: 326A. 28. Laidler P, Dulińska J, Lekka M: Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys 2005, 435: 1–14.PubMedCrossRef 29. Moul JW: Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur Urol 1999, 35: 399–407.PubMedCrossRef 30. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G: Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009, 15: 167–172.PubMedCrossRef 31. Heidtmann HH, Nettelbeck DM, Mingels A, Jäger R, Welker HG, Kontermann RE: Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 1999, 81: 1269–1273.PubMedCrossRef 32. Sivridis E, PARP cancer Giatromanolaki A, Koukourakis MI: Tumor Angiogenesis Is Associated with MUC1 Overexpression and Loss of Prostate-specific Antigen Expression in Prostate Cancer. Clin Cancer Res 2001, 7: 1533–1538.PubMed 33.